Tyra Biosciences, Inc. (Nasdaq: TYRA), a California-based clinical-stage biotechnology company involved in developing medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced on Tuesday that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.

The presentation will highlight preclinical data on TYRA-300, Tyra's lead investigational FGFR3-selective inhibitor. The poster, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be presented by Jacqueline H. Starrett, Ph.D., on July 13, 2025, from 12:00 PM to 1:30 PM during Session P70 on rare bone and genetic disorders.

TYRA-300, developed through Tyra's proprietary SNÅP platform, is currently in clinical development for both oncology and genetic skeletal disorders. It is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia that the company says has demonstrated interim clinical proof-of-concept results in metastatic urothelial cancer (mUC).

Planned Phase 2 trials for TYRA-300 include SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer.